MOR208C201
Laufzeit: 01.01.2013 - 31.12.2016
imported
Kurzfassung
A phase IIa, open-label, multicenter study of single-agent MOR00208, an Fc-optimized anti-CD19 antibody, in patients with relapsed or refractory B-cell Non-Hodgkin’s lymphoma
